MediPharm Labs Corp.
LABS.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -131.18% | -14.49% | 23.53% | -44.34% | 89.93% |
| Total Depreciation and Amortization | -7.23% | -29.12% | -19.72% | -43.32% | -49.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.86% | 138.47% | -73.16% | -62.65% | -57.50% |
| Change in Net Operating Assets | 81.92% | 111.58% | 54.53% | 146.79% | -704.44% |
| Cash from Operations | 71.77% | 140.93% | 76.37% | -70.51% | -85.41% |
| Capital Expenditure | 97.61% | 100.00% | 52.07% | 25.67% | -87.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 19,952.94% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 97.61% | 100.00% | 1,477.27% | 11,966.41% | -107.52% |
| Total Debt Issued | -- | -- | -100.00% | -33.24% | -- |
| Total Debt Repaid | 30.57% | 33.83% | 94.76% | 45.10% | 1.49% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -17.86% | -49.37% | 135.00% | -65.17% | -72.41% |
| Cash from Financing | 31.87% | 24.67% | 96.75% | -35.46% | -197.14% |
| Foreign Exchange rate Adjustments | 48.65% | 36.01% | -133.33% | 79.74% | 24.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.12% | 115.90% | 107.58% | 302.99% | -189.12% |